Research on PSMA-Targeted Intraoperative Fluorescent Imaging Agents

Prior treatment

• History of allergy (≥2 drugs/foods, milk/pollen), or allergy to investigational drug/components.
• Alcohol abuse (\>14 units/week) in prior 3 months or positive breathalyzer.
• Positive urine drug screen, drug abuse history (past 5 years), or illicit drug use (past 3 months).
• Surgery within prior 3 months.
• Participation in another clinical trial (investigational product) within prior 3 months.
• Prescription medication use within prior 1 month.
• OTC drugs, herbal supplements, or vitamins within prior 48 hours.

Other illness

• Clinically significant abnormalities (physical exam, vital signs, ECG, labs) or severe medical history (cardiac, hepatic, renal, GI, neurological, respiratory, psychiatric, metabolic) deemed unsuitable by the investigator.
• Positive serology for HBsAg, anti-HCV, anti-HIV, or syphilis.
• Other conditions deemed unsuitable by the investigator.

Lab values

• Blood loss \>400 mL or platelet donation (2 therapeutic units) in prior 3/1 months, respectively.

Other

• Subjects will be excluded if any of the following apply:
• Smoking \>5 cigarettes/day (past 3 months) and inability to abstain.

• Provide signed informed consent prior to the trial, and fully understand the trial content, procedures, and potential adverse reactions.
• Be able to complete the study as required by the trial protocol.
• Be an adult male aged 18-65 years (inclusive).
• Have a body weight ≥50 kg and a body mass index (BMI) of 18-30 kg/m² (calculated as BMI = weight \[kg\]/height² \[m²\]).
• Neither the subject nor their partner/spouse plan to conceive or donate sperm from screening until 3 months after the trial completion, and agree to use effective non-pharmacological contraception during the study.